CJC-1295 No DAC and Ipamorelin: Pre-Cycle vs Post-Cycle Research

There is no pre-cycle product and no post-cycle product. What exists are two different research questions: one that characterises a model before an intervention window, and one that characterises it after. CJC-1295 no DAC is a growth-hormone-releasing hormone (GHRH) analog; ipamorelin is a selective growth hormone secretagogue acting at the ghrelin receptor — two separate signalling pathways, which is exactly why investigators study them in sequence and in combination rather than as substitutes. For a wholesale buyer, the difference that matters is procurement mechanics: pre-window work is front-loaded and lot-sensitive, post-window work runs long and lot-continuity-sensitive, and the two produce very different reorder patterns and documentation loads. Both compounds are research use only.

Two research windows, two different questions

The "pre-cycle versus post-cycle" phrasing arrived from consumer forums, not from the literature, and it is worth separating the vocabulary from the underlying science before you build a catalog around it.

CJC-1295 without the drug affinity complex — often catalogued as modified GRF (1-29) — is a GHRH analog with a short circulating half-life relative to the DAC-conjugated version. That short window is the whole point of the molecule in research settings: it produces a defined, time-bounded signal rather than a prolonged one, which makes it useful when an investigator needs a discrete stimulus they can time against a measurement. Ipamorelin acts on a different receptor entirely, and preclinical research suggests selective secretagogues of this class produce a distinct pattern of signalling from GHRH analogs. Because the two pathways are separate, studies indicate that combined and sequential designs are examined precisely to isolate additive versus independent effects — not because one is a "starter" and the other an "advanced" compound.

So what do the two windows actually mean operationally?

Pre-window research is baseline characterisation. The investigator is establishing what the model looks like before any intervention: reference measurements, assay validation, variability within the cohort, instrument calibration. This work is usually compressed into a short calendar period, uses smaller quantities, and is brutally sensitive to material consistency — if the baseline is drawn against one lot and the intervention runs on another, the comparison is compromised before it starts.

Post-window research is follow-up characterisation: what the measured parameters look like after the intervention window closes, how quickly they return toward baseline, and whether any observed change persists. This work tends to run considerably longer, consumes more material overall, and generates a much larger paper trail because every measurement point must be traceable to a specific lot and a specific certificate of analysis.

The reason a wholesale buyer should care is simple: your customers' research design determines your reorder curve. A catalog built for one-off baseline purchases behaves nothing like a catalog serving longitudinal follow-up work, and the supplier practices that are merely annoying in the first case become disqualifying in the second.

Side-by-side: where the two windows diverge

Read the table as a purchasing brief rather than a research brief. If the accounts you serve skew toward baseline work, speed of fulfilment and identity confirmation carry the most weight. If they skew toward follow-up work, the ability to source the same lot repeatedly — or at minimum to document cleanly when a lot changes — is worth more than a marginally better unit price.

Lot continuity, order minimums, and how tier pricing actually works

Wholesale pricing in research peptides is built on volume commitment, and the structure is more consistent across the industry than the numbers are. Tiers generally reward either total order value or per-SKU quantity, and the discount behaves like a step function rather than a smooth curve: you cross a threshold and the unit economics change. Margins vary widely with volume, compound category, and how deeply you commit per SKU, which is why any supplier quoting you a single universal markup figure is describing a sales pitch rather than a pricing model.

Minimum order quantities exist for a reason worth understanding. Synthesis, lyophilisation, and analytical testing are batch processes with largely fixed costs. A batch that is tested seven ways costs roughly the same to test whether it yields a few hundred vials or a few thousand, so per-unit pricing improves as the tested batch is amortised across more units. That same economics explains why lot continuity and price tiers are linked: committing to a larger draw from a single lot is both cheaper for you and better for your customers' comparability.

For mixed pre- and post-window demand, two purchasing patterns tend to work. The first is anchoring: commit volume on the SKUs your accounts reorder predictably — CJC-1295 No DAC and Ipamorelin frequently move together in growth-factor research catalogs — and buy adjacent compounds at lower tiers until demand proves itself. The second is calendar alignment: ask whether a supplier can reserve or flag remaining inventory from a specific lot, so a customer mid-study is not forced onto new material at the worst possible moment. Not every supplier can do this, and the answer tells you a great deal about how the operation is run.

What you should refuse to accept is opacity. Pricing that only appears after a sales call, tiers that shift between quotes, or minimums that are described differently in writing than on the phone are all signals of a program that is negotiating rather than publishing. A wholesale program you can plan against is one where the tier structure, the application process, and the testing documentation are all stated up front.

What to verify before you commit to a supplier

This is the part of the decision that has nothing to do with research design and everything to do with whether your account will survive contact with a demanding customer.

Purity method, not just a purity number. Ask which analytical method produced the figure. High-performance liquid chromatography is the standard for purity; mass spectrometry confirms identity. A purity claim without a named method and a lot number attached is a marketing statement.

Purity versus net peptide content. These are different measurements and buyers conflate them constantly. Purity describes the proportion of the peptide-related material that is the target sequence; net peptide content describes how much actual peptide is in the vial versus counterions, residual moisture, and excipients. Ask for both, and ask which one the vial label refers to.

What a testing panel actually covers. If a supplier advertises a seven-panel batch test, ask which seven assays are in it and whether identity, purity, and contamination screening are all represented. "We test every batch" is not a specification.

Whether the COA is verifiable by you. There is a meaningful difference between a supplier emailing you a PDF and a supplier publishing lab results you can look up independently against a lot number. Ask whether COAs are publicly accessible, whether they are lot-matched to what ships, and whether historical COAs remain retrievable after the lot sells out — that last one matters enormously for follow-up research that closes out months after purchase.

Charging for documentation. Some suppliers sell COAs separately or release them only on request after purchase. Treat paid or gated test results as a red flag; the documentation is part of the product, not an upsell.

Fulfilment origin and timeline. Ask where orders ship from and what the realistic window is. For accounts running longitudinal work, a predictable domestic timeline is usually worth more than a cheaper unit price with an unpredictable customs exposure.

Application and account process. A legitimate wholesale program qualifies its buyers. If anyone with a credit card can buy at wholesale pricing, the program is a discount code, not a partnership.

The questions that belong with your counsel, not your supplier

Everything in this section is informational and is not legal advice.

Whether your business may stock, resell, or repackage research-use-only compounds is not a question a supplier can answer for you, and you should be sceptical of any supplier who tries. The framework varies by jurisdiction and by business model, and it is generally shaped by more than one authority — state boards, professional licensing bodies, and federal regulators each look at different aspects. The right move is to bring your attorney a specific written description of what you intend to do and ask targeted questions: How is my entity classified for this activity? Does reselling in original manufacturer packaging differ from any handling or relabelling? What licensure, registration, or recordkeeping applies to my structure in my state? What does my professional board say about the category, and has that position changed recently? Which representations may I make in my own marketing?

Nothing here should be read as a conclusion that any particular activity is permitted or prohibited where you operate — that determination is your counsel's, informed by your state board. If your questions extend to any applied use in animals, that conversation belongs with a licensed veterinarian and not with a supplier; research-use-only material is not supplied for administration to humans or animals, and no dosing, protocol, or administration guidance appears anywhere in this article or in product documentation.

What Real Peptides does differently

Real Peptides publishes the specifications most buyers have to extract from a sales call. Compounds are produced to 99%+ HPLC purity, and every batch runs through seven-panel testing rather than a single purity check. Certificates of analysis are publicly verifiable — the reader can check the lab results directly against a lot rather than relying on a PDF forwarded by a rep — which is the practical difference between telling a customer the material was tested and showing them. Orders are fulfilled from within the US in 5–7 days, which makes reorder cadence something a partner can actually forecast. Access runs through a 3-step wholesale application, so the program qualifies its buyers instead of handing wholesale pricing to anyone who finds the page.

For a buyer serving both baseline and follow-up research, those four facts map directly onto the failure modes described above: verifiable lot-matched documentation addresses traceability, published purity and panel testing address identity confidence, and a stated domestic fulfilment window addresses continuity risk.

Where a qualified buyer goes from here

If your accounts are asking about GHRH analogs and secretagogues and you want pricing you can plan a catalog around, the Wholesale Partner Program application is the path. It takes three steps, and the outcome is tier pricing, lot-matched documentation, and a fulfilment timeline you can quote to your own customers without hedging.

Related reading and catalog pages: CJC-1295 No DAC 10mg, Ipamorelin 10mg, and Tesamorelin 10mg sit within the broader Growth Factor & Tissue Signaling Research collection, and buyers building a first wholesale order often start from the Popular Peptides collection before committing volume on any single SKU.